Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724314 | 0.86 | HDAC8 (0.47) | HDAC8PTPN1 | |
| SCHEMBL864877 | 0.86 | DPP4 (0.50) | HDAC8PTPN1 | |
| SCHEMBL864907 | 0.84 | ESR2 (0.48) | HDAC8PTPN1UCHL1 | |
| SCHEMBL864906 | 0.84 | ESR2 (0.48) | HDAC8PTPN1UCHL1 | |
| SCHEMBL7989939 | 0.84 | HDAC8 (0.48) | HDAC8PTPN1 | |
| SCHEMBL7988510 | 0.82 | UCHL1 (0.52) | HDAC8UCHL1 | |
| SCHEMBL1724947 | 0.81 | PTPN1 (0.44) | HDAC8PTPN1 | |
| SCHEMBL5126474 | 0.80 | PTPN1 (0.67) | HDAC8PTPN1 | |
| SCHEMBL7977798 | 0.80 | HDAC8 (0.45) | HDAC8PTPN1UCHL1 | |
| SCHEMBL7743681 | 0.78 | PTPN1 (0.54) | HDAC8PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| EP-2406247-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | HDAC8 2636/4885PTPN1 3970/4885UCHL1 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.